BGI Genomics Co., Ltd. (300676.SZ)
CNY 48.2
(-0.52%)
CNY 48.2
(-0.52%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -3.63 Billion CNY | 13.67% |
| 2022 | -4.21 Billion CNY | 26.37% |
| 2021 | -5.72 Billion CNY | -38.59% |
| 2020 | -4.12 Billion CNY | -508.13% |
| 2019 | -678.71 Million CNY | 34.68% |
| 2018 | -1.03 Billion CNY | -14.44% |
| 2017 | -907.93 Million CNY | -21.76% |
| 2016 | -745.64 Million CNY | -46.7% |
| 2015 | -508.28 Million CNY | -1.86% |
| 2014 | -499 Million CNY | -56.74% |
| 2013 | -318.37 Million CNY | 9.55% |
| 2012 | -352 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -3.46 Billion CNY | -6.52% |
| 2024 Q1 | -3.25 Billion CNY | 10.51% |
| 2024 Q3 | -3.43 Billion CNY | 0.99% |
| 2023 Q2 | -4 Billion CNY | 9.15% |
| 2023 Q4 | -3.63 Billion CNY | 9.98% |
| 2023 FY | -3.63 Billion CNY | 13.67% |
| 2023 Q1 | -4.41 Billion CNY | -4.79% |
| 2023 Q3 | -4.03 Billion CNY | -0.74% |
| 2022 Q4 | -4.21 Billion CNY | 26.07% |
| 2022 Q3 | -5.69 Billion CNY | 6.79% |
| 2022 Q2 | -6.11 Billion CNY | -16.64% |
| 2022 FY | -4.21 Billion CNY | 26.37% |
| 2022 Q1 | -5.23 Billion CNY | 8.4% |
| 2021 Q1 | -5.89 Billion CNY | -42.82% |
| 2021 Q4 | -5.72 Billion CNY | 6.74% |
| 2021 Q3 | -6.13 Billion CNY | -13.98% |
| 2021 FY | -5.72 Billion CNY | -38.59% |
| 2021 Q2 | -5.38 Billion CNY | 8.71% |
| 2020 Q4 | -4.12 Billion CNY | -37.2% |
| 2020 FY | -4.12 Billion CNY | -508.13% |
| 2020 Q1 | -1.03 Billion CNY | -53.05% |
| 2020 Q2 | -2.11 Billion CNY | -103.82% |
| 2020 Q3 | -3 Billion CNY | -42.08% |
| 2019 Q4 | -678.71 Million CNY | 9.27% |
| 2019 FY | -678.71 Million CNY | 34.68% |
| 2019 Q3 | -748.06 Million CNY | 12.61% |
| 2019 Q2 | -855.97 Million CNY | 22.21% |
| 2019 Q1 | -1.1 Billion CNY | -5.9% |
| 2018 Q4 | -1.03 Billion CNY | 11.1% |
| 2018 Q1 | -1.08 Billion CNY | -19.74% |
| 2018 Q2 | -1.36 Billion CNY | -25.23% |
| 2018 FY | -1.03 Billion CNY | -14.44% |
| 2018 Q3 | -1.16 Billion CNY | 14.16% |
| 2017 FY | -907.93 Million CNY | -21.76% |
| 2017 Q3 | -735.54 Million CNY | -26.93% |
| 2017 Q1 | -762.36 Million CNY | -2.24% |
| 2017 Q2 | -579.5 Million CNY | 23.99% |
| 2017 Q4 | -907.93 Million CNY | -23.44% |
| 2016 Q1 | 2.37 Billion CNY | 567.51% |
| 2016 Q4 | -745.64 Million CNY | 0.0% |
| 2016 FY | -745.64 Million CNY | -46.7% |
| 2015 Q2 | -399.45 Million CNY | 0.0% |
| 2015 Q4 | -508.28 Million CNY | 0.0% |
| 2015 FY | -508.28 Million CNY | -1.86% |
| 2015 Q1 | -399.45 Million CNY | 0.0% |
| 2014 FY | -499 Million CNY | -56.74% |
| 2013 FY | -318.37 Million CNY | 9.55% |
| 2012 FY | -352 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.31 Billion CNY | 375.799% |
| Hangzhou Tigermed Consulting Co., Ltd. | -4.06 Billion CNY | 10.496% |
| Dirui Industrial Co.,Ltd. | -131.62 Million CNY | -2662.45% |
| Beijing Strong Biotechnologies, Inc. | 411.59 Million CNY | 983.394% |
| Medicalsystem Biotechnology Co., Ltd. | -850.71 Million CNY | -327.404% |
| Maccura Biotechnology Co.Ltd | -170.79 Million CNY | -2028.886% |
| Guangzhou Wondfo Biotech Co.,Ltd | -240.75 Million CNY | -1410.223% |
| Guangdong Hybribio Biotech Co.,Ltd. | -708.27 Million CNY | -413.353% |
| Amoy Diagnostics Co., Ltd. | -92.73 Million CNY | -3820.971% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -486.57 Million CNY | -647.254% |